Elite in Achondroplasia

Paul Arundel

Sheffield, ENG, GB 
Elite in Achondroplasia
Sheffield, ENG, GB 
OverviewLocationsClinical Research

Overview

Paul Arundel practices in Sheffield, United Kingdom. Mr. Arundel is rated as an Elite expert by MediFind in the treatment of Achondroplasia. His top areas of expertise are Achondroplasia, Acanthosis Nigricans, Osteogenesis Imperfecta, and Chondrodystrophy.

His clinical research consists of co-authoring 50 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 4 clinical trials in the study of Achondroplasia.

Gender
Male

Locations

Sheffield, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom
Complex And Atypical Oi, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
Enrollment Status: Enrolling_by_invitation
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
Enrollment Status: Completed
Publish Date: April 13, 2021
View 3 Less Clinical Trials

50 Total Publications

An observational study of the prevalence of classic metaphyseal fractures in children with osteogenesis imperfecta in the first two years of life.
An observational study of the prevalence of classic metaphyseal fractures in children with osteogenesis imperfecta in the first two years of life.
Journal: Clinical radiology
Published: January 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Arundel's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile